- Home
- RDHL vs VIVS Comparison
RDHL vs VIVS Comparison
Compare RDHL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- VIVS
- Stock Information
- Founded
- RDHL 2009
- VIVS 2007
- Country
- RDHL Israel
- VIVS United States
- Employees
- RDHL N/A
- VIVS N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDHL Health Care
- VIVS Health Care
- Exchange
- RDHL Nasdaq
- VIVS Nasdaq
- Market Cap
- RDHL 3.9M
- VIVS 4.7M
- IPO Year
- RDHL N/A
- VIVS N/A
- Fundamental
- Price
- RDHL $1.88
- VIVS $3.19
- Analyst Decision
- RDHL
- VIVS
- Analyst Count
- RDHL 0
- VIVS 0
- Target Price
- RDHL N/A
- VIVS N/A
- AVG Volume (30 Days)
- RDHL 2.9M
- VIVS 166.7K
- Earning Date
- RDHL 09-05-2025
- VIVS 11-07-2025
- Dividend Yield
- RDHL N/A
- VIVS N/A
- EPS Growth
- RDHL N/A
- VIVS N/A
- EPS
- RDHL N/A
- VIVS N/A
- Revenue
- RDHL $9,550,000.00
- VIVS $142,000.00
- Revenue This Year
- RDHL $381.91
- VIVS $42.38
- Revenue Next Year
- RDHL N/A
- VIVS $15.42
- P/E Ratio
- RDHL N/A
- VIVS N/A
- Revenue Growth
- RDHL 157.62
- VIVS 94.52
- 52 Week Low
- RDHL $1.06
- VIVS $1.41
- 52 Week High
- RDHL $9.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- RDHL 52.80
- VIVS 51.15
- Support Level
- RDHL $1.89
- VIVS $2.90
- Resistance Level
- RDHL $2.61
- VIVS $3.48
- Average True Range (ATR)
- RDHL 0.23
- VIVS 0.34
- MACD
- RDHL 0.01
- VIVS -0.09
- Stochastic Oscillator
- RDHL 22.22
- VIVS 20.86
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.